[
  {
    "ts": "2025-09-19T20:05:42+00:00",
    "headline": "Why Amgen (AMGN) Stock Is Trading Up Today",
    "summary": "Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder.",
    "url": "https://finance.yahoo.com/news/why-amgen-amgn-stock-trading-200542355.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "0fce1194-1f6b-389f-b5d9-354db71ab6dc",
      "content": {
        "id": "0fce1194-1f6b-389f-b5d9-354db71ab6dc",
        "contentType": "STORY",
        "title": "Why Amgen (AMGN) Stock Is Trading Up Today",
        "description": "",
        "summary": "Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder.",
        "pubDate": "2025-09-19T20:05:42Z",
        "displayTime": "2025-09-19T20:05:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AMGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cVRDvNeMN6SVWgnyfhcabA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/khfuGqTIKrJ0BdS6OOusRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-stock-trading-200542355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-stock-trading-200542355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-19T20:02:50+00:00",
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200250877.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "209ff5ba-931a-36a7-8354-dfed870428e7",
      "content": {
        "id": "209ff5ba-931a-36a7-8354-dfed870428e7",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Mixed Late Afternoon",
        "description": "",
        "summary": "Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and",
        "pubDate": "2025-09-19T20:02:50Z",
        "displayTime": "2025-09-19T20:02:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200250877.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200250877.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "INCR.TA"
            },
            {
              "symbol": "SPRY"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-19T17:17:10+00:00",
    "headline": "EMA Backs Amgen Drug For Rare Autoimmune Disorder",
    "summary": "The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammation in one or multiple organs. There are cu",
    "url": "https://finance.yahoo.com/news/ema-backs-amgen-drug-rare-171710015.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "eb0ac7ca-66ed-3337-96f5-5a54e978ec89",
      "content": {
        "id": "eb0ac7ca-66ed-3337-96f5-5a54e978ec89",
        "contentType": "STORY",
        "title": "EMA Backs Amgen Drug For Rare Autoimmune Disorder",
        "description": "",
        "summary": "The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammation in one or multiple organs. There are cu",
        "pubDate": "2025-09-19T17:17:10Z",
        "displayTime": "2025-09-19T17:17:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/e70c4ae195b6a99b39868b00af1ce584",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "EMA Backs Amgen Drug For Rare Autoimmune Disorder",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E2usgYN6L7fOtOR7l82wRA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/e70c4ae195b6a99b39868b00af1ce584.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qkWtLCe1PhUfPCZqf7.SwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/e70c4ae195b6a99b39868b00af1ce584.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ema-backs-amgen-drug-rare-171710015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ema-backs-amgen-drug-rare-171710015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-19T13:54:48+00:00",
    "headline": "Amgen's Uplizna Receives European Human Medicines Committee Recommendation for IgG4-Related Disease",
    "summary": "Amgen's (AMGN) Uplizna has received a positive opinion from the European Medicines Agency's (EMA) hu",
    "url": "https://finance.yahoo.com/news/amgen-apos-uplizna-receives-european-135448614.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "305ef149-0052-33e9-978b-e9e48b06b2bc",
      "content": {
        "id": "305ef149-0052-33e9-978b-e9e48b06b2bc",
        "contentType": "STORY",
        "title": "Amgen's Uplizna Receives European Human Medicines Committee Recommendation for IgG4-Related Disease",
        "description": "",
        "summary": "Amgen's (AMGN) Uplizna has received a positive opinion from the European Medicines Agency's (EMA) hu",
        "pubDate": "2025-09-19T13:54:48Z",
        "displayTime": "2025-09-19T13:54:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-apos-uplizna-receives-european-135448614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-apos-uplizna-receives-european-135448614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]